You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

DIHYDROERGOTAMINE MESYLATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Dihydroergotamine Mesylate patents expire, and what generic alternatives are available?

Dihydroergotamine Mesylate is a drug marketed by Gland Pharma Ltd, Hikma, Hikma Pharms, Padagis Us, Provepharm Sas, Sagent Pharms Inc, Amneal, Cipla, and Rubicon. and is included in ten NDAs.

The generic ingredient in DIHYDROERGOTAMINE MESYLATE is dihydroergotamine mesylate. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dihydroergotamine Mesylate

A generic version of DIHYDROERGOTAMINE MESYLATE was approved as dihydroergotamine mesylate by PADAGIS US on April 28th, 2003.

  Try a Trial

Drug patent expirations by year for DIHYDROERGOTAMINE MESYLATE
Drug Prices for DIHYDROERGOTAMINE MESYLATE

See drug prices for DIHYDROERGOTAMINE MESYLATE

Recent Clinical Trials for DIHYDROERGOTAMINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ache Laboratorios Farmaceuticos S.A.Phase 3
Xijing HospitalPhase 2/Phase 3
Satsuma Pharmaceuticals, Inc.Phase 3

See all DIHYDROERGOTAMINE MESYLATE clinical trials

Pharmacology for DIHYDROERGOTAMINE MESYLATE
Medical Subject Heading (MeSH) Categories for DIHYDROERGOTAMINE MESYLATE

US Patents and Regulatory Information for DIHYDROERGOTAMINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gland Pharma Ltd DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 215623-001 Aug 18, 2023 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Amneal DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate SPRAY, METERED;NASAL 214105-001 Jan 4, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Padagis Us DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 040475-001 Apr 28, 2003 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Cipla DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate SPRAY, METERED;NASAL 212907-001 May 20, 2020 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hikma DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 040453-001 Jun 9, 2003 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hikma Pharms DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 206621-001 Sep 15, 2017 AP RX No Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.